Stocks and Investing Stocks and Investing
Tue, December 3, 2019
Mon, December 2, 2019

Brian Skorney Downgraded (BIIB) to Sell and Held Target at $250 on, Dec 2nd, 2019


Published on 2024-10-26 18:43:56 - WOPRAI, Brian Skorney
  Print publication without navigation


Brian Skorney of Baird, Downgraded "Biogen Inc." (BIIB) to Sell and Held Target at $250 on, Dec 2nd, 2019.

Brian has made no other calls on BIIB in the last 4 months.



There are 11 other peers that have a rating on BIIB. Out of the 11 peers that are also analyzing BIIB, 3 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Cory Kasimov of "JP Morgan" Maintained at Hold with Increased Target to $260 on, Wednesday, October 23rd, 2019
  • Ian Somaiya of "BMO Capital" Maintained at Hold with Increased Target to $297 on, Wednesday, October 23rd, 2019
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $305 on, Wednesday, October 23rd, 2019


These are the ratings of the 8 analyists that currently disagree with Brian


  • Robyn Karnauskas of "SunTrust Robinson Humphrey" Initiated at Strong Buy and Held Target at $337 on, Tuesday, November 12th, 2019
  • Aaron Gal of "Bernstein" Upgraded from Hold to Buy on, Wednesday, October 30th, 2019
  • Adnan Butt of "Guggenheim" Upgraded from Hold to Strong Buy on, Wednesday, October 23rd, 2019
  • Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy with Increased Target to $335 on, Wednesday, October 23rd, 2019
  • Evan Seigerman of "Credit Suisse" Maintained at Sell with Increased Target to $260 on, Wednesday, October 23rd, 2019
  • Marc Goodman of "SVB Leerink" Upgraded from Hold to Buy and Increased Target to $350 on, Wednesday, October 23rd, 2019
  • Matthew Harrison of "Morgan Stanley" Maintained at Sell with Increased Target to $262 on, Wednesday, October 23rd, 2019
  • Phil Nadeau of "Cowen & Co." Maintained at Buy with Increased Target to $325 on, Wednesday, October 23rd, 2019
Contributing Sources